ranpirnase immunotoxin fusion protein (Immunomedics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameranpirnase immunotoxin fusion protein (Immunomedics)

Drug Alias Name2L-Rap-hRS7 (Immunomedics)22-RapE1-Rap2L-Rap-hRS7Rap-hRS7

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4]

Mechanisms of ActionCD226 antigen blockersRibonucleases stimulantsTumor-associated calcium signal transducer 2 modulators

TargetsCD226 antigenTumor-associated calcium signal transducer 2Ribonucleases

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A